TrialPath

Find a study

Match me to a study

404 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

147 studies on the map

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) — Digestive Health Specialsits, DothanUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis — University of Michigan, Ann ArborEffect of Mediterranean Diet in Inflammatory Bowel Disease — University of California, San Diego, San DiegoMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanComparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD) — University of North Carolina at Chapel Hill, Chapel HillMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease — Digestive Health Specialsits, DothanLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease — Mirador Therapeutics Selected Site, BirminghamPragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults — University of Alabama at Birmingham, BirminghamStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease — Digestive Health Specialists /ID# 266216, DothanA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — University of South Alabama (USA) Physicians Group, MobileA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Sun City Clinical Research, GlendaleEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeClinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease — Phoenix Children's Hospital, PhoenixThe Reducing REVISITS Study: A Cluster RCT — University of Chicago, ChicagoA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanTreat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission — Hoag Hospital, IrvineA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Research Site, FoleyEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Chandler Clinical Research Trials- Site Number : 8400025, ChandlerA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Research Site, CullmanA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — UAB Lung Health Center, BirminghamTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) — Phoenix Children's Hospital, PhoenixRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — GSK Investigational Site, SheffieldA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterA Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — AZ Gastro Care - Chandler, ChandlerA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. — GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020, Sun CitymyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home — UAB School of Medicine/Lung Health Center, BirminghamBOOM-IBD2 Pivotal Clinical Trial — Gastroenterology Medical Clinic (Objective Health), FolsomClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, BirminghamBronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 — University of Alabama at Birmingham, BirminghamA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CityA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema — Banner University Medical Center, PhoenixSPIROMICS Study of Early COPD Progression (SOURCE) — University of Alabama at Birmingham, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, BirminghamA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Gastro Health Research- St. Vincents East, BirminghamCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsVOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study — GI Alliance - Sun City, Sun CitySotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordSTRIVE Post-Market Registry Study — Dignity Health St. Joseph's Hospital and Medical Center, PhoenixTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleSPYRAL GEMINI Pilot Study — Stanford Hospital and Clinics, StanfordHyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC) — University of Alabama Medicine, BirminghamTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, BirminghamA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — UCSF Medical Center at Mission Bay, San FranciscoAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanA Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — One of a Kind Clinical Research Center, ScottsdalePragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD — Minneapolis VA Health Care System, MinneapolisA Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease — Knowledge Research Center, OrangeMulti-Center Clean Air Randomized Controlled Trial in COPD — University of Alabama, Lung Health Center, BirminghamStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockEvaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD — University of Alabama-Birmingham Hospital - UAB Lung Health Center, BirminghamMirikizumab Real World Protocol — South Denver Gastroenterology, DenverA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) — Connecticut Clinical Research Institute ( Site 0297), BristolA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesZymfentra (Infliximab-dyyb) REal World Cohort STudy — Yale University School of Medicine, New HavenMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamStudy of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention — Tulane University, New OrleansEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneStudy of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis — Massachusetts General Hospital, BostonPiMZ Longitudinal Cohort (PiMZ Logic) — University of Alabama at Birmingham, BirminghamBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraDB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease — Direct Biologics Investigational Site, AuroraA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimFunctional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention — Boise VA Medical Center, BoiseClosed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital — The University of Alabama at Birmingham, BirminghamCOPD Exacerbation Follow Up — Advocate Lutheran General Hospital, Park RidgeA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesSupporting Health in Veterans With Heart Failure — VA Clinic - Gainesville, GainesvilleTesting the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease — Atlanta VA Medical and Rehab Center, Decatur, GA, DecaturStudy to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis — Bausch Health Site 008, Garden GroveCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, DecaturA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Research Site, AthensSymptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS — Clinical Research of West Florida, Inc., ClearwaterVECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease — TLC Clinical Research Inc - Los Angeles, Los AngelesDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) — GSK Investigational Site, Loxahatchee GrovesR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaDevelopment of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy — Mayo Clinic- Rochester, RochesterVNS Prospective Neuromodulation of Immune and Gastrointestinal Systems — Norton Healthcare, LouisvilleA Multi Center Study Testing a New Implant for Adults With Severe Emphysema — University of California, San Francisco, San FranciscoEffect of Ensifentrine on Sputum Markers of Inflammation in COPD — University of Alabama at Birmingham, BirminghamPRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD. — University of Colorado, DenverALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool — Med-Care Research Corp, MiamiMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaCOMPARE - Pediatric Inflammatory Bowel Disease (PIBD) — University of North Carolina at Chapel Hill, Chapel HillCharacterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System — Hope Center, Washington D.C.Military Health and Nutrition Examination Study — Fort Campbell, Fort CampbellAmerican Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study) — NIDDK-Phoenix Epidemiology and Clinical Research, PhoenixLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordReverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial — Children's Hospital of Philadelphia, PhiladelphiaPulmonary Rehabilitation for Rural Patients With COPD — Mayo Clinic in Arizona, ScottsdaleAcoustic Waveform Respiratory Evaluation — Indiana University, IndianapolisSupporting Evidence-based Responses to Emotional Needs in Emphysema — Henry Ford Health System, DetroitStandardized Microbiota Transplant Therapy in Crohn's Disease — University of Minnesota, MinneapolisOpen-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD — Digestive & Liver Center of Florida, OrlandoA Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis — Rush University Medical Center, ChicagoHelmsley 3.0: Abbreviated MRE — Mayo Clinic, RochestereValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — GSK Investigational Site, DoralFeasibility of The Health Integrated Nutrition and Kidney Wellness Program — UPMC Kidney Clinic - Wexford, PittsburghCardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment — Fountains Family Care, ChandlerFood and Fitness With Medicine (FFWM) — Ohio State Healthy Community Center, ColumbusTezspire Cardiac Events PASS — Healthcare Integrated Research Database (HIRD), WilmingtonUrine Metabolites in the Diagnosis of Disease — Unio Health Partners (Gastroenterology), Encinitas

Showing the 150 nearest — narrow your filters for fewer, closer studies.